SHAREHOLDER ALERT: Brower Piven Encourages Investors With Substantial Losses From Investment in Edwards Lifesciences Corporation

SHAREHOLDER ALERT: Brower Piven Encourages Investors With Substantial Losses
From Investment in Edwards Lifesciences Corporation to Contact Brower Piven
Before the November 18, 2013 Lead Plaintiff Deadline -- EW

STEVENSON, Md., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A
Professional Corporation announces that a class action lawsuit has been
commenced in the United States District Court for the Central District of
California on behalf of purchasers of Edwards Lifesciences Corporation
("Edwards Lifesciences" or the "Company") (NYSE:EW) common stock during the
period between April 25, 2012 and April 23, 2013, inclusive (the "Class
Period").

If you have suffered a net loss from investment in Edwards Lifesciences
Corporation common stock purchased on or after April 25, 2012, and held
through the revelation of negative information on April 23, 2013, as described
below, at no cost to you, you may obtain additional information about this
lawsuit and your ability to become a lead plaintiff by contacting Brower Piven
at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling
410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley
Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than November 18, 2013 and be selected
by the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
the Company during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period that physicians' use of SAPIEN, the Company's transcatheter aortic
heart valve, was weaker than the Company claimed because of concerns among
physicians over the risks and complexity of the procedure for implanting the
valve and that the Company's outlook for sales and earnings per share was
significantly weaker than the optimistic guidance defendants offered to
investors. According to the complaint, following the Company's August 23, 2013
disclosure that approximately twenty candidate hospitals had postponed SAPIEN
training, that there was substantially no backlog of patients awaiting SAPIEN
implants, and that the Company's financial results had been and would likely
continue to be weaker than estimates, the value of Edwards Lifesciences shares
declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven
         Brower Piven, A Professional Corporation
         Stevenson, Maryland
         410/415-6616
         hoffman@browerpiven.com
 
Press spacebar to pause and continue. Press esc to stop.